ClinicalTrials.gg
CompletedNCT03025698Updated Aug 10, 2026Results posted

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

A Phase 2 interventional study of Eltrombopag and hATG in Aplastic Anemia, sponsored by Novartis Pharmaceuticals. Completed at 20 sites in 6 countries. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing eltrombopag in Anemia, Aplastic — 3 open to participants now, 3 under way, 1 of them phase 3. eltrombopag · Anemia, Aplastic.

Enrollment
6th of 17
51 · median 36
Started
2017
with 1 other
Phase 2
11 of 17
1 open now
Registered
10th of 17
by date
Lead sponsor
6 of 17
Novartis Pharmaceuticals

Among the 17 studies testing eltrombopag in Anemia, Aplastic, this one is the 6th largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 2, and was the 10th registered.

Anemia, Aplastic

372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

3 of the 17 studies testing eltrombopag in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing eltrombopag in Anemia, Aplastic, or all of them as a file.
02

Study summary

This is a phase II, open label, multi-center, intra-patient dose escalation study to characterize the pharmacokinetics (PK) after oral administration of eltrombopag in combination with immunosuppressive therapy in pediatric patients with previously untreated or relapsed/refractory severe aplastic anemia (SAA) or recurrent aplastic anemia (AA).

Read the detailed description

All patients were treated with eltrombopag for the 26-week Treatment Period, followed by a 52-week Follow-Up Period. Patients who had been previously untreated with immunosuppressive therapy were treated according to the standard of care, hATG plus cyclosporine plus eltrombopag. Patients with relapsed/refractory SAA or recurrent AA were enrolled into one of two treatment options: hATG plus cyclosporine plus eltrombopag or cyclosporine plus eltrombopag, depending on prior treatment with immunosuppressive therapy. Patients could receive eltrombopag beyond 26 weeks if the investigator thought that the patient was still receiving clinical benefit from the drug.

After initiating treatment with eltrombopag, patients had their dose assessed and modified as tolerated, until the targeted platelet count or maximum dose was achieved. Pharmacokinetic assessments were performed at time points intended to capture steady state PK of the starting dose and highest dose achieved.

There are four separate periods of this study: Screening (signing of written informed consent through Day -1), Treatment (for 26 weeks), Follow-up (additional 52 weeks), and Long-term Follow-up (for additional 3 years). The first 3 periods were considered the Core phase of the study.

Study completion (Core) will occur when the last patient completes the 26-week treatment and 52-week Follow-up Period [at Week 78].

03

Conditions studied

  • Aplastic Anemia

Browse trials for

Keywords

  • Eltrombopag
  • Horse anti-thymocyte globulin
  • Cyclosporine
  • previously untreated or relapsed severe aplastic anemia
  • recurrent aplastic anemia
  • Severe aplastic anemia
  • Pharmacokinetics
  • Immunosuppressive therapy
  • ETB115
  • Refractory
04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Cohort A patients:

  • History of prior diagnosis of SAA,
  • Diagnosis of SAA or recurrent AA following treatment for SAA, as per Section 5.1. Patients with recurrent AA (e.g., losing their response) are exempt from meeting the diagnostic criteria for SAA relapse at the time of study enrollment, but must have been previously diagnosed with SAA.
  • Agree to concurrent eltrombopag treatment with appropriate, investigator-selected therapy (IST) with either hATG + CsA or CsA.

For Cohort B patients:

  • Diagnosis of SAA at time of enrollment.
  • Patients must not have been previously treated with IST, and must meet all criteria as described in Table 5-1.
  • Patients must agree to treatment with hATG + CsA concurrent with eltrombopag.

All patients eligible for inclusion in this study must meet all of the following criteria:

  • Age 1 to \<18 years.
  • Assessments to rule out congenital/inherited bone marrow failure syndromes and other causes of immune-mediated pancytopenia, which may be treated with transplant, must be completed prior to enrollment.
  • Hematopoietic stem cell transplantation () is not suitable or available as a treatment option or has been refused by the patient. (Candidacy for HSCT will be determined as per local practices or national guidelines.)
  • Bone marrow aspirate and at any time during the 4 weeks prior to first dose of eltrombopag.
  • Performance status score: ≥50 for patients 16 years of age and older or Lansky ≥50 for patients below 16 years of age.
  • Written must be signed by a parent or legal guardian prior to initiation of any study specific procedure.
  • Normal karyotype within 4 weeks prior to first dose of eltrombopag. If there are insufficient metaphases (\< 10) to determine karyotype, a repeat marrow aspirate is required. If upon repeat bone marrow aspirate, the number of metaphases is insufficient (\< 10), then FISH probes performed in marrow aspirate as per protocol must be normal.

Exclusion criteria

Exclusion Criteria:

  • Prior and/or active medical history of:

    • Fanconi anemia (via chromosome breakage test or growth arrest by flow cytometry)
    • Other known underlying inherited marrow failure syndrome (such as but not limited to Dyskeratosis Congenita, Congenital Amegakaryocytic Thrombocytopenia, or Shwachman-Diamond Syndrome).
  • Symptomatic Paroxysmal Nocturnal Hemoglobinuria (PNH) and/or PNH clones >50% of White blood cell (WBC) or Red blood cell (RBC) at time of enrollment.

    • Any cytogenetic abnormalities by karyotyping or FISH.
    • Myelodysplastic syndrome (MDS)
    • Other known or suspected underlying primary immunodeficiency
    • Any
  • Active infection not responding to appropriate therapy.
  • Prior eltrombopag or other thrombopoietin receptor (TPO-R) agonist treatment for at least 2 months and a lack of response.
  • Have any of the following out-of-range laboratory values:

    • Serum Creatinine >2.5 × (ULN),
    • (AST) or alanine aminotransferase (ALT) >3 × ULN.
  • Concurrent participation in an study within 30 days prior to enrollment or within 5-half-lives of the investigational product, whichever is longer. Note: a parallel enrollment in a registry for patients with SAA or AA is acceptable.

Pregnant or nursing (lactating) women.

  • Female patients of (e.g., are menstruating or could reach menarche during the study, this usually includes girls 9 years and older) who do not agree to abstinence or, if sexually active, do not agree to the use of as defined in Section 7.2.1.2.6 (pregnancy section) of the protocol. If local regulations are more stringent than the contraception methods listed in this protocol to prevent pregnancy, local regulations apply and will be described in the ICF.
  • Male patients who are sexually active and do not agree to abstinence or to use a condom during intercourse while taking eltrombopag, and for 13 weeks after stopping treatment.
  • Patients, who in the investigators' opinion may be unwilling, are unable or unlikely to comply with the requirements of the study protocol.
  • Known immediate or delayed reaction or idiosyncrasy to drugs chemically related to eltrombopag or its , CSA, or hATG that contraindicates patient participation.
  • History of major surgery, serious illness, or traumatic injury within 4 weeks of first dose of study treatment.
  • Patients with known history of positivity.
  • Patients with known history of or C positivity.
  • Any severe and/or uncontrolled medical conditions which could cause unacceptable safety risks or compromise compliance with the protocol, such as:

    • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome),Active skin, mucosa, ocular or GI disorders of Grade > 1.
  • Impaired cardiac function, such as:

    • Patients with a history of congenital long syndrome or known family history of long QTc syndrome,
    • Corrected QTc >450 msec using Fridericia correction (QTcF) on the screening (using triplicate ECGs),
    • Ventricular arrhythmias and or other cardiac arrhythmia not controlled with medication,
    • Other cardio-vascular disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension),
    • History of known structural abnormalities (e.g., cardiomyopathy).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Cohort A (Option 1)

    hATG (ATGAM®), CsA and eltrombopag begin on Day 1.

    Drug: Eltrombopag · Drug: hATG · Drug: CsA

  • Experimental
    Cohort A (option 2)

    CsA and eltrombopag begin on Day 1.

    Drug: Eltrombopag · Drug: CsA

  • Experimental
    Cohort B

    hATG (ATGAM®), CsA and eltrombopag begin on Day 1.

    Drug: Eltrombopag · Drug: hATG · Drug: CsA

Interventions

  • Tablet for oral use, once daily or Powder for oral suspension (PfOS), once daily

    Also known as: ETB115

  • DrughATG

    Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)

  • DrugCsA

    Cyclosporine (CsA) was supplied as either oral capsules or oral solution, administered twice a day.

06

What researchers measure

Primary outcomes

  1. Eltrombopag PK Parameters: AUCtau, AUClast

    AUC tau: Area under the curve calculated to the end of the dosing interval ( tau) (mass\*time/volume) AUC last: Area under the curve calculated to the last quantifiable concentration point (Tlast) (mass\*time/volume)

    Time frame: at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78

  2. Eltrombopag PK Parameter: Cmax

    Cmax is the observed maximum plasma concentration following administration (mass/volume)

    Time frame: at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78

  3. Eltrombopag PK Parameter: Ctrough at the Highest Dose Level

    Ctrough is the pre-dose plasma concentration (mass/volume).

    Time frame: at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78

Secondary outcomes

  1. Percentage of Participants With an Overall Response Rate and Percentage of Participants With a Platelet Response Rate Based on Per Pediatric Committee of European Medicines Agency (PDCO)

    Overall response rate (ORR) is defined as the percentage of participants who have achieved a complete response (CR) or partial response (PR) or No response (NR) by the Investigator. CR criteria: Platelet (PLT) and red blood cell (RBC) transfusion independence, Normal age-adjusted Hgb, PLT \>100 × 10\^9/L and absolute neutrophil count (ANC) \>1.5 × 10\^9/L. PR: PLT and RBC Transfusion independence and at least 2 of the following criteria: Reticulocytes \>30 × 10\^9/L, PLT \>30 × 10\^9/L, ANC \>1.5 x 10\^9L. PLT transfusion independence is defined as a period for at least 28 days without PLT transfusion. Platelet response rate (PRR): Platelet response rate is comprised of CR + PR based on the following criteria: CR: PLT \>100 × 10\^9/L; PR: PLT \>30 × 10\^9/L; NR: PLT transfusion within 4 weeks or PLT \<= 30 × 10\^9/L.

    Time frame: Week 12, Week 26, Week 52, Week 78

  2. Hematologic Counts (Platelets (Blood), Neutrophils (Blood))

    Individual Platelets (PLT) and neutrophil counts were summarized for all participants.

    Time frame: Week 12, Week 26, Week 52, Week 78, Week 130, Week 182, Week 234

  3. Hematologic Counts (Hemoglobin (Blood))

    Individual hemoglobin (Hgb) counts were summarized for all participants.

    Time frame: Week 12, Week 26, Week 52, Week 78, Week 130, Week 182, Week 234

  4. Number of Red Blood Cells (RBC) Transfusions

    Number of transfusions during the treatment period refers to total number of RBC transfusions participants have received while on treatment.

    Time frame: From date of first dose to approx. 4.5 years

  5. Frequency of Red Blood Cell (RBC) Transfusions

    Frequency of transfusions during the treatment period refers to number of RBC transfusions during the treatment period divided by number of months of treatment duration.

    Time frame: From date of first dose to approx. 4.5 years

  6. Number of Platelet (PLT) Transfusions

    Number of transfusions during the treatment period refers to total number of PLT transfusions participants have received while on treatment.

    Time frame: From date of first dose to approx. 4.5 years

  7. Frequency of Platelet (PLT) Transfusions

    Frequency of transfusions during the treatment period refers to number of PLT transfusions during the treatment period divided by number of months of treatment duration.

    Time frame: From date of first dose to approx. 4.5 years

  8. Total Duration of Red Blood Cell (RBC) Transfusion Independence During the Treatment Period

    RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. Duration of RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. First transfusion duration was calculated as the date of the day before the first transfusion after baseline minus the date of first exposure eltrombopag + 1.

    Time frame: From date of first dose to approx. 4.5 years

  9. Total Duration of Platelet (PLT) Transfusion Independence During the Treatment Period

    Platelet transfusion independence during the treatment period is defined as the duration from the first day of the 28-day period without PLT transfusion until the occurrence of a PLT transfusion after the period free from any PLT transfusion. Duration of PLT transfusion independence is defined as a period of time of at least 28 days without platelet transfusion. First transfusion duration was calculated as the date of the day before the first transfusion after baseline minus the date of first exposure eltrombopag + 1.

    Time frame: From date of first dose to approx. 4.5 years

  10. Maximum Duration of Red Blood Cell (RBC) Transfusion Independence

    RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. Maximum duration of RBC transfusion independence is defined as the maximum duration among the durations of RBC transfusion independence. First transfusion duration was calculated as the date of first transfusion after baseline minus the date of first exposure eltrombopag + 1.

    Time frame: From date of first dose to approx. 4.5 years

  11. Maximum Duration of Platelet (PLT) Transfusion Independence

    Maximum duration of PLT transfusion independence is defined as the maximum duration among the durations of PLT transfusion independence. First transfusion duration was calculated as the date of first transfusion after baseline minus the date of first exposure eltrombopag + 1.

    Time frame: From date of first dose to approx. 4.5 years

  12. Overall Bone Marrow Cellularity

    Percentage of cells in bone marrow biopsy - a comprehensive diagnostic evaluation to distinguish between the various bone marrow disorders.

    Time frame: Screening, Week 26, Week 52, Week 78, Week 130, Week 182, Week 234

  13. Bone Marrow Morphology

    Percentage of morphology (erythropoiesis, granulopoiesis, megakaryopoiesis, CD34+ (blast cells) cells in bone marrow aspirate - a comprehensive diagnostic evaluation to distinguish between the various bone marrow disorders.

    Time frame: Screening, Week, 26, Week 52, Week 78, Week 130, Week 182, Week 234

  14. Bone Marrow Cytogenetics

    Number of bone marrow cytogenetics (chromosomal structure) by kryotyping and Fluorescence in situ hybridization (FISH). This is a comprehensive diagnostic evaluation to distinguish between the various bone marrow disorders.

    Time frame: Screening, Week 12, Week 26, Week 52, Week 78, Week 130, Week 182, Week 234

  15. Acceptability and Palatability for Both Tablets and Powder Formulation for Oral Solution (PfOS)

    Standardized (total) summary score, ranged from 0-100, (where 0 means worst and 100 means the best), was derived from all items from the questionnaire based on a scoring matrix. The questionnaire was completed by parents and caregivers of patients under 12 years of age (ObsRO) and a questionnaire completed by patients 12 years and older (PRO).

    Time frame: any day from Day 1 of drug initiation up to Week 78

  16. Clonal Evolution to Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Percentage of participants with clonal evolution to Paroxysmal Nocturnal Hemoglobinuria (PNH).

    Time frame: Baseline, Week (W) 26 Day (D) 1, W52D1, W78D1, W130D1, W182D1, W234D1

  17. Exposure (AUCtau) - Response Relationship of Eltrombopag and Best Overall Response Rate by Age Groups

    Pharmacokinetic parameter (AUCtau) of eltrombopag at the highest dose in relationship to best overall response rate in regard to complete response (CR), partial response (PR) and no response (NR). AUC tau: Area under the curve calculated to the end of the dosing interval (tau) (mass\*time/volume)

    Time frame: at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78

  18. Exposure (Cmax, Ctrough) - Response Relationship of Eltrombopag and Best Overall Response Rate by Age Groups

    Pharmacokinetic parameters (Cmax and Ctrough) of eltrombopag at the highest dose in relationship to overall response rate in regard to complete response (CR), partial response (PR) and no response (NR). Cmax is the observed maximum plasma concentration following administration (mass/volume). Ctrough is the pre-dose plasma concentration (mass/volume).

    Time frame: at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78

  19. Exposure (AUCtau) - Response Relationship of Eltrombopag and Best Platelet Response Rate by Age Groups

    Pharmacokinetic parameter (AUCtau) of eltrombopag at the highest dose in relationship to platelet response rate. AUC tau: Area under the curve calculated to the end of the dosing interval ( tau) (mass\*time/volume)

    Time frame: at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78

  20. Exposure (Cmax, Ctrough) - Response Relationship of Eltrombopag and Best Platelet Response Rate by Age Groups

    Pharmacokinetic parameters (Cmax and Ctrough) of eltrombopag at the highest dose in relationship to platelet response rate. Cmax is the observed maximum plasma concentration following administration (mass/volume). Ctrough is the pre-dose plasma concentration (mass/volume).

    Time frame: at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78

  21. Alternate Overall Response Rate (aORR)

    Alternate overall responses were derived using hematological parameters (i.e., hemoglobin, platelet, reticulocyte, and ANC). aORR is defined as the percentage of participants who achieved an alternate complete response (aCR) or an alternate partial response (aPR)

    Time frame: Week 12, Week 26, Week 52, Week 78

  22. Pharmacokinetics (PK) of Eltrombopag at the Starting Dose (AUCtau)

    PK parameter, AUCtau. AUC tau: Area under the curve calculated to the end of the dosing interval (tau) (mass\*time/volume)

    Time frame: Week 3 Day 1

  23. PK of Eltrombopag at the Starting Dose (Cmax)

    PK parameter, Cmax Cmax is the observed maximum plasma concentration following administration (mass/volume)

    Time frame: Week 3 Day 1

  24. PK of Eltrombopag at the Starting Dose (Ctrough)

    PK parameter, Ctrough Ctrough is the pre-dose plasma concentration (mass/volume).

    Time frame: Week 3 Day 1

07

Results

Posted Aug 10, 2026

Participant flow

Study was conducted in 19 sites in 6 countries

Participant flow — Overall Study
MilestoneCohort A: Regimen 1Cohort A: Regimen 2Cohort B
Started10437
Participants who entered 26-week treatment phase10437
Completed 26-week (wk) treatment7425
Entered 52-wk post-treatment follow up phase 1 (wk 78)9426
Did not enter 52-wk post-treatment f/u phase (wk 78)1011
Entered 3-year post-treatment follow-up 26319
Did not complete ptfu2119
Completed5210
Not completed5227
Withdrew: Adverse event002
Withdrew: Physician decision308
Withdrew: Progressive disease003
Withdrew: Participant/guardian decision2111
Withdrew: Lost to follow-up001
Withdrew: Death010
Withdrew: Completed study treatment/discontinued study for unspecified reasons002

Outcome measures

PrimaryEltrombopag PK Parameters: AUCtau, AUClast

AUC tau: Area under the curve calculated to the end of the dosing interval ( tau) (mass\*time/volume) AUC last: Area under the curve calculated to the last quantifiable concentration point (Tlast) (mass\*time/volume)

Time frame:
at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78
Reported as:
Geometric mean · hr*ng/mL
Eltrombopag PK Parameters: AUCtau, AUClast
hr*ng/mLCohort A: Regimen 1 (1 to <6 Years)Cohort A: Regimen 1 (6 to <18 Years)Cohort A: Regimen 2 (6 to <18 Years)Cohort B (1 to < 6 Years)Cohort B (6 to <18 Years)
AUCtau272000285000 ± 72.4406000502000 ± 65.6275000 ± 52.6
AUClast272000300000 ± 60.2166000 ± 196477000 ± 52.5259000 ± 75.1
PrimaryEltrombopag PK Parameter: Cmax

Cmax is the observed maximum plasma concentration following administration (mass/volume)

Time frame:
at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78
Reported as:
Geometric mean · ng/mL
Eltrombopag PK Parameter: Cmax
ng/mLCohort A: Regimen 1 ( 1 to <6 Years)Cohort A: Regimen 1 (6 to <18 Years)Cohort A: Regimen 2 (6 to <18 Years)Cohort B (1 to < 6 Years)Cohort B (6 to <18 Years)
Eltrombopag PK Parameter: Cmax1610014500 ± 66.714300 ± 56.727100 ± 40.615600 ± 47.2
PrimaryEltrombopag PK Parameter: Ctrough at the Highest Dose Level

Ctrough is the pre-dose plasma concentration (mass/volume).

Time frame:
at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78
Reported as:
Geometric mean · ng/mL
Eltrombopag PK Parameter: Ctrough at the Highest Dose Level
ng/mLCohort A: Regimen 1 (1 to <6 Years)Cohort A: Regimen 1 (6 to <18 Years)Cohort A: Regimen 2 (6 to <18 Years)Cohort B (1 to < 6 Years)Cohort B (6 to <18 Years)
Eltrombopag PK Parameter: Ctrough at the Highest Dose Level54709930 ± 68.79900 ± 32.313400 ± 1139670 ± 64.5
SecondaryPercentage of Participants With an Overall Response Rate and Percentage of Participants With a Platelet Response Rate Based on Per Pediatric Committee of European Medicines Agency (PDCO)

Overall response rate (ORR) is defined as the percentage of participants who have achieved a complete response (CR) or partial response (PR) or No response (NR) by the Investigator. CR criteria: Platelet (PLT) and red blood cell (RBC) transfusion independence, Normal age-adjusted Hgb, PLT \>100 × 10\^9/L and absolute neutrophil count (ANC) \>1.5 × 10\^9/L. PR: PLT and RBC Transfusion independence and at least 2 of the following criteria: Reticulocytes \>30 × 10\^9/L, PLT \>30 × 10\^9/L, ANC \>1.5 x 10\^9L. PLT transfusion independence is defined as a period for at least 28 days without PLT transfusion. Platelet response rate (PRR): Platelet response rate is comprised of CR + PR based on the following criteria: CR: PLT \>100 × 10\^9/L; PR: PLT \>30 × 10\^9/L; NR: PLT transfusion within 4 weeks or PLT \<= 30 × 10\^9/L.

Time frame:
Week 12, Week 26, Week 52, Week 78
Reported as:
Number · Percentage of participants
Percentage of Participants With an Overall Response Rate and Percentage of Participants With a Platelet Response Rate Based on Per Pediatric Committee of European Medicines Agency (PDCO)
Percentage of participantsCohort A: Regimen 1Cohort A: Regimen 2Cohort B
ORR: Week 1230.0 (6.7 to 65.2)50.0 (6.8 to 93.2)13.5 (4.5 to 28.8)
ORR: Week 2670.0 (34.8 to 93.3)75.0 (19.4 to 99.4)45.9 (29.5 to 63.1)
ORR: Week 5250.0 (18.7 to 81.3)50.0 (6.8 to 93.2)43.2 (27.1 to 60.5)
ORR: Week 7850.0 (18.7 to 81.3)75.0 (19.4 to 99.4)40.5 (24.8 to 57.9)
PRR: Week 1250.0 (18.7 to 81.3)75.0 (19.4 to 99.4)43.2 (27.1 to 60.5)
PRR: Week 2660.0 (26.2 to 87.8)75.0 (19.4 to 99.4)54.1 (36.9 to 70.5)
PRR: Week 5250.0 (18.7 to 81.3)75.0 (19.4 to 99.4)48.6 (31.9 to 65.6)
PRR: Week 7850.0 (18.7 to 81.3)75.0 (19.4 to 99.4)45.9 (29.5 to 63.1)
SecondaryHematologic Counts (Platelets (Blood), Neutrophils (Blood))

Individual Platelets (PLT) and neutrophil counts were summarized for all participants.

Time frame:
Week 12, Week 26, Week 52, Week 78, Week 130, Week 182, Week 234
Reported as:
Median · x 10^9 cells/L
Hematologic Counts (Platelets (Blood), Neutrophils (Blood))
x 10^9 cells/LCohort A: Regimen 1Cohort A: Regimen 2Cohort B
Week 12: Platelets (blood)40.500 (5.00 to 260.00)73.500 (17.00 to 172.00)50.000 (3.00 to 338.00)
Week 26: Platelets (blood)60.500 (3.00 to 222.00)122.500 (49.00 to 182.00)106.000 (3.00 to 230.00)
Week 52: Platelets (blood)147.000 (7.00 to 164.00)160.500 (22.00 to 240.00)163.000 (28.00 to 318.00)
Week 78: Platelets (blood)133.500 (6.00 to 308.00)140.000 (88.00 to 273.00)152.500 (28.00 to 278.00)
Week 130: Platelets (blood)155.000 (43.00 to 195.00)138.500 (128.00 to 149.00)139.000 (31.00 to 245.00)
Week 182: Platelets (blood)173.000 (9.00 to 221.00)149.000 (127.00 to 171.00)182.000 (104.00 to 223.00)
Week 234: Platelets (blood)176.000 (110.00 to 196.00)129.000 (129.00 to 129.00)189.000 (147.00 to 264.00)
Week 12: Neutrophils (blood)1.795 (0.72 to 11.72)1.555 (1.01 to 4.15)1.100 (0.00 to 8.10)
Week 26: Neutrophils (blood)2.495 (0.52 to 4.60)1.258 (0.78 to 1.63)1.640 (0.40 to 4.47)
Week 52: Neutrophils (blood)3.110 (0.17 to 4.29)1.721 (1.11 to 3.47)2.600 (0.83 to 5.75)
Week 78: Neutrophils (blood)3.617 (1.02 to 4.91)1.234 (0.56 to 1.34)2.292 (0.69 to 5.41)
Week 130: Neutrophils (blood)2.732 (1.04 to 6.72)0.892 (0.57 to 1.21)1.690 (1.30 to 2.67)
Week 182: Neutrophils (blood)3.014 (1.00 to 6.09)1.471 (0.61 to 2.33)3.100 (2.07 to 4.30)
Week 234: Neutrophils (blood)2.630 (2.04 to 4.40)1.200 (1.20 to 1.20)2.078 (1.02 to 4.70)
SecondaryHematologic Counts (Hemoglobin (Blood))

Individual hemoglobin (Hgb) counts were summarized for all participants.

Time frame:
Week 12, Week 26, Week 52, Week 78, Week 130, Week 182, Week 234
Reported as:
Median · g/L
Hematologic Counts (Hemoglobin (Blood))
g/LCohort A: Regimen 1Cohort A: Regimen 2Cohort B
Week 1289.5 (64 to 131)87.0 (81 to 94)88.0 (57 to 130)
Week 26101.0 (59 to 128)98.5 (93 to 102)95.0 (44 to 125)
Week 52116.0 (52 to 138)104.5 (95 to 117)110.0 (92 to 133)
Week 78118.5 (67 to 138)92.0 (89 to 119)117.0 (97 to 148)
Week 130119.5 (88 to 141)125.5 (122 to 129)126.0 (109 to 142)
Week 182126.0 (96 to 138)125.5 (115 to 136)127.0 (66 to 129)
Week 234126.0 (116 to 147)128.0 (128 to 128)125.0 (110 to 144)
SecondaryNumber of Red Blood Cells (RBC) Transfusions

Number of transfusions during the treatment period refers to total number of RBC transfusions participants have received while on treatment.

Time frame:
From date of first dose to approx. 4.5 years
Reported as:
Median · RBC transfusions
Number of Red Blood Cells (RBC) Transfusions
RBC transfusionsCohort A: Regimen 1Cohort A: Regimen 2Cohort B
approx. 3 years7.0 (1 to 17)3.0 (1 to 34)7.0 (1 to 26)
approx. 4.5 years7.0 (1 to 17)3.0 (1 to 34)7.0 (1 to 26)
SecondaryFrequency of Red Blood Cell (RBC) Transfusions

Frequency of transfusions during the treatment period refers to number of RBC transfusions during the treatment period divided by number of months of treatment duration.

Time frame:
From date of first dose to approx. 4.5 years
Reported as:
Median · RBC transfusions per month
Frequency of Red Blood Cell (RBC) Transfusions
RBC transfusions per monthCohort A: Regimen 1Cohort A: Regimen 2Cohort B
approx. 3 years (n = 8, 3, 33)1.5 (0 to 4)0.2 (0 to 3)0.9 (0 to 5)
approx. 4.5 years (n = 8, 3, 33)1.5 (0 to 4)0.2 (0 to 3)0.9 (0 to 5)
SecondaryNumber of Platelet (PLT) Transfusions

Number of transfusions during the treatment period refers to total number of PLT transfusions participants have received while on treatment.

Time frame:
From date of first dose to approx. 4.5 years
Reported as:
Median · Platelet transfusions
Number of Platelet (PLT) Transfusions
Platelet transfusionsCohort A: Regimen 1Cohort A: Regimen 2Cohort B
approx. 3 years13.0 (3 to 48)53.0 (53 to 53)13.0 (2 to 65)
approx. 4.5 years13.0 (3 to 48)53.0 (53 to 53)13.0 (2 to 65)
SecondaryFrequency of Platelet (PLT) Transfusions

Frequency of transfusions during the treatment period refers to number of PLT transfusions during the treatment period divided by number of months of treatment duration.

Time frame:
From date of first dose to approx. 4.5 years
Reported as:
Median · Platelet transfusions per month
Frequency of Platelet (PLT) Transfusions
Platelet transfusions per monthCohort A: Regimen 1Cohort A: Regimen 2Cohort B
approx. 3 years2.0 (0 to 14)4.2 (4.2 to 4.2)2.0 (0 to 13)
approx. 4.5 years2.0 (0 to 14)4.2 (4.2 to 4.2)2.0 (0 to 13)
SecondaryTotal Duration of Red Blood Cell (RBC) Transfusion Independence During the Treatment Period

RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. Duration of RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. First transfusion duration was calculated as the date of the day before the first transfusion after baseline minus the date of first exposure eltrombopag + 1.

Time frame:
From date of first dose to approx. 4.5 years
Reported as:
Median · days
Total Duration of Red Blood Cell (RBC) Transfusion Independence During the Treatment Period
daysCohort A: Regimen 1Cohort A: Regimen 2Cohort B
approx. 3 years355.0 (185 to 860)430.0 (262 to 558)267.0 (58 to 1074)
approx. 4.5 years355.0 (185 to 1637)430.0 (262 to 558)267.0 (58 to 1296)
SecondaryTotal Duration of Platelet (PLT) Transfusion Independence During the Treatment Period

Platelet transfusion independence during the treatment period is defined as the duration from the first day of the 28-day period without PLT transfusion until the occurrence of a PLT transfusion after the period free from any PLT transfusion. Duration of PLT transfusion independence is defined as a period of time of at least 28 days without platelet transfusion. First transfusion duration was calculated as the date of the day before the first transfusion after baseline minus the date of first exposure eltrombopag + 1.

Time frame:
From date of first dose to approx. 4.5 years
Reported as:
Median · days
Total Duration of Platelet (PLT) Transfusion Independence During the Treatment Period
daysCohort A: Regimen 1Cohort A: Regimen 2Cohort B
approx. 3 years252.0 (36 to 860)360.5 (139 to 560)268.0 (34 to 1100)
approx. 4.5 years252.0 (36 to 1637)360.5 (139 to 560)268.0 (34 to 1322)
SecondaryMaximum Duration of Red Blood Cell (RBC) Transfusion Independence

RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. Maximum duration of RBC transfusion independence is defined as the maximum duration among the durations of RBC transfusion independence. First transfusion duration was calculated as the date of first transfusion after baseline minus the date of first exposure eltrombopag + 1.

Time frame:
From date of first dose to approx. 4.5 years
Reported as:
Median · days
Maximum Duration of Red Blood Cell (RBC) Transfusion Independence
daysCohort A: Regimen 1Cohort A: Regimen 2Cohort B
approx. 3 years355.0 (185 to 860)321.0 (262 to 430)259.0 (58 to 1074)
approx. 4.5 years355.0 (185 to 1637)321.0 (262 to 430)262.0 (58 to 1296)
SecondaryMaximum Duration of Platelet (PLT) Transfusion Independence

Maximum duration of PLT transfusion independence is defined as the maximum duration among the durations of PLT transfusion independence. First transfusion duration was calculated as the date of first transfusion after baseline minus the date of first exposure eltrombopag + 1.

Time frame:
From date of first dose to approx. 4.5 years
Reported as:
Median · days
Maximum Duration of Platelet (PLT) Transfusion Independence
daysCohort A: Regimen 1Cohort A: Regimen 2Cohort B
approx. 3 years252.0 (36 to 860)360.5 (64 to 560)249.5 (34 to 1067)
approx. 4.5 years252.0 (36 to 1637)360.5 (64 to 560)249.5 (34 to 1289)
SecondaryOverall Bone Marrow Cellularity

Percentage of cells in bone marrow biopsy - a comprehensive diagnostic evaluation to distinguish between the various bone marrow disorders.

Time frame:
Screening, Week 26, Week 52, Week 78, Week 130, Week 182, Week 234
Reported as:
Median · Percentage of cells
Overall Bone Marrow Cellularity
Percentage of cellsCohort A: Regimen 1Cohort A: Regimen 2Cohort B
Overall cellularity (OC): Screening11.5 (5.0 to 30.0)32.5 (20.0 to 50.0)4.0 (2.0 to 40.0)
OC: Week 2630.0 (10.0 to 50.0)30.0 (20.0 to 50.0)22.5 (2.0 to 55.0)
OC: Week 5235.0 (5.0 to 45.0)50.0 (50.0 to 65.0)35.0 (3.0 to 55.0)
OC: Week 7832.5 (5.0 to 50.0)50.0 (50.0 to 50.0)35.0 (3.0 to 70.0)
OC: Week 13045.0 (40.0 to 50.0)45.0 (45.0 to 45.0)40.0 (10.0 to 60.0)
OC: Week 182——52.5 (45.0 to 60.0)
OC: Week 23452.5 (30.0 to 55.0)—47.5 (25.0 to 60.0)
Hematologic cellularity (HC): Screening5.0 (1.0 to 25.0)22.5 (10.0 to 45.0)1.5 (1.0 to 25.0)
HC: Week 2621.0 (5.0 to 45.0)25.0 (15.0 to 40.0)17.5 (1.0 to 50.0)
HC: Week 5230.0 (30.0 to 40.0)45.0 (45.0 to 45.0)27.5 (2.0 to 50.0)
HC: Week 7825.0 (3.0 to 40.0)40.0 (40.0 to 40.0)30.0 (2.0 to 50.0)
HC: Week 13035.0 (30.0 to 40.0)35.0 (35.0 to 35.0)35.0 (8.0 to 50.0)
HC: Week 182——60.0 (40.0 to 80.0)
HC: Week 23445.0 (25.0 to 50.0)—37.5 (20.0 to 50.0)
SecondaryBone Marrow Morphology

Percentage of morphology (erythropoiesis, granulopoiesis, megakaryopoiesis, CD34+ (blast cells) cells in bone marrow aspirate - a comprehensive diagnostic evaluation to distinguish between the various bone marrow disorders.

Time frame:
Screening, Week, 26, Week 52, Week 78, Week 130, Week 182, Week 234
Reported as:
Median · Percentage of cells
Bone Marrow Morphology
Percentage of cellsCohort A: Regimens 1Cohort A: Regimen 2Cohort B
Erythroid cells: Screening11.5 (0.0 to 28.0)27.0 (19.0 to 39.0)5.0 (0.0 to 38.0)
Erythroid cells: Week 2610.0 (1.0 to 25.0)12.0 (2.0 to 22.0)18.0 (0.0 to 55.0)
Erythroid cells: Week 5213.0 (4.0 to 37.0)12.0 (2.0 to 17.0)14.5 (1.0 to 28.0)
Erythroid cells: Week 7814.0 (5.0 to 20.0)15.0 (15.0 to 15.0)20.5 (4.0 to 26.0)
Erythroid cells: Week 13022.0 (22.0 to 22.0)15.0 (15.0 to 15.0)17.0 (5.0 to 32.0)
Erythroid cells: Week 184——11.0 (7.0 to 15.0)
Erythroid cells: Week 23413.0 (5.0 to 20.0)—18.0 (13.0 to 33.0)
Neutrophil: Screening33.0 (1.0 to 48.0)29.5 (19.0 to 48.0)8.0 (0.0 to 45.0)
Neutrophil cells: Week 2652.0 (34.0 to 63.0)47.0 (29.0 to 66.0)50.0 (17.0 to 78.0)
Neutrophil: Week 5248.5 (32.0 to 59.0)62.0 (57.0 to 67.0)52.5 (20.0 to 76.0)
Neutrophil: Week 7843.0 (4.0 to 54.0)53.0 (53.0 to 53.0)52.0 (34.0 to 67.0)
Neutrophil cells: Week 13044.0 (44.0 to 44.0)51.0 (51.0 to 51.0)53.0 (39.0 to 65.0)
Neutrophil cells: Week 182——31.0 (5.0 to 57.0)
Neutrophil cells: Week 23443.5 (30.0 to 56.0)—33.5 (25.0 to 36.0)
Blast cells: Screening0.00 (0.0 to 1.0)1.0 (0.0 to 5.0)0.0 (0.0 to 3.0)
Blast cells: Week 260.0 (0.0 to 2.0)1.0 (0.0 to 2.0)0.0 (0.0 to 1.0)
Blast cells: Week 520.0 (0.0 to 1.0)1.0 (0.0 to 2.0)0.0 (0.0 to 1.0)
Blast cells: Week 780.0 (0.0 to 1.0)0.0 (0.0 to 0.0)1.0 (0.0 to 2.0)
Blast cells: Week 1300.0 (0.0 to 0.0)0.0 (0.0 to 0.0)1.0 (0.0 to 2.0)
Blast cells: Week 182——13.0 (0.0 to 26.0)
Blast cells: Week 2340.0 (0.0 to 2.0)—1.0 (0.0 to 2.0)
SecondaryBone Marrow Cytogenetics

Number of bone marrow cytogenetics (chromosomal structure) by kryotyping and Fluorescence in situ hybridization (FISH). This is a comprehensive diagnostic evaluation to distinguish between the various bone marrow disorders.

Time frame:
Screening, Week 12, Week 26, Week 52, Week 78, Week 130, Week 182, Week 234
Reported as:
Count of participants · Participants
Bone Marrow Cytogenetics
ParticipantsCohort A: Regimen 1Cohort A: Regimen 2Cohort B
FISH Chr 7 @ Screening — Normal10426
FISH Chr 7 @ Screening — Abnormal000
FISH Chr 7 @ Screening — Not Available002
FISH Chr 7 @ Week 12 — Normal9226
FISH Chr 7 @ Week 12 — Abnormal000
FISH Chr 7 @ Week 12 — Not Available001
FISH Chr 7 @ Week 26 — Normal8328
FISH Chr 7 @ Week 26 — Abnormal000
FISH Chr 7 @ Week 26 — Not Available101
FISH Chr 7 @ Week 52 — Normal6315
FISH Chr 7 @ Week 52 — Abnormal000
FISH Chr 7 @ Week 52 — Not Available001
FISH Chr 7 @ Week 78 — Normal6113
FISH Chr 7 @ Week 78 — Abnormal000
FISH Chr 7 @ Week 78 — Not Available002
FISH Chr 7 @ Week 130 — Normal219
FISH Chr 7 @ Week 130 — Abnormal000
FISH Chr 7 @ Week 130 — Not Available101
FISH Chr 7 @ Week 182 — Normal318
FISH Chr 7 @ Week 182 — Abnormal000
FISH Chr 7 @ Week 182 — Not Available000
FISH Chr 7 @ Week 234 — Normal404
FISH Chr 7 @ Week 234 — Abnormal000
FISH Chr 7 @ Week 234 — Not Available000
Karyotype @ Screening — Normal8419
Karyotype @ Screening — Abnormal000
Karyotype @ Screening — Not Available208
Karyotype @ Week 12 — Normal8225
Karyotype @ Week 12 — Abnormal100
Karyotype @ Week 12 — Not Available006
Karyotype @ Week 26 — Normal7325
Karyotype @ Week 26 — Abnormal101
Karyotype @ Week 26 — Not Available105
Karyotype @ Week 52 — Normal5315
Karyotype @ Week 52 — Abnormal000
Karyotype @ Week 52 — Not Available002
Karyotype @ Week 78 — Normal4113
Karyotype @ Week 78 — Abnormal100
Karyotype @ Week 78 — Not Available102
Karyotype @ Week 130 — Normal218
Karyotype @ Week 130 — Abnormal000
Karyotype @ Week 130 — Not Available202
Karyotype @ Week 182 — Normal317
Karyotype @ Week 182 — Abnormal001
Karyotype @ Week 182 — Not Available000
Karyotype @ Week 234 — Normal404
Karyotype @ Week 234 — Abnormal000
Karyotype @ Week 234 — Not Available000
SecondaryAcceptability and Palatability for Both Tablets and Powder Formulation for Oral Solution (PfOS)

Standardized (total) summary score, ranged from 0-100, (where 0 means worst and 100 means the best), was derived from all items from the questionnaire based on a scoring matrix. The questionnaire was completed by parents and caregivers of patients under 12 years of age (ObsRO) and a questionnaire completed by patients 12 years and older (PRO).

Time frame:
any day from Day 1 of drug initiation up to Week 78
Reported as:
Median · scores on a scale (of acceptability)
Acceptability and Palatability for Both Tablets and Powder Formulation for Oral Solution (PfOS)
scores on a scale (of acceptability)Cohort A: Regimen 1Cohort A: Regimen 2Cohort B
Acceptability (including palatability) - Tablet71.0 (58.0 to 96.0)75.0 (58.0 to 88.0)71.0 (46.0 to 96.0)
Acceptability (including palatability) - PfOS——71.0 (32.0 to 82.0)
SecondaryClonal Evolution to Paroxysmal Nocturnal Hemoglobinuria (PNH)

Percentage of participants with clonal evolution to Paroxysmal Nocturnal Hemoglobinuria (PNH).

Time frame:
Baseline, Week (W) 26 Day (D) 1, W52D1, W78D1, W130D1, W182D1, W234D1
Reported as:
Number · Percentage of participants
Clonal Evolution to Paroxysmal Nocturnal Hemoglobinuria (PNH)
Percentage of participantsCohort A: Regimen 1Cohort A: Regimen 2Cohort B
Baseline: Positive clonal evolution20.025.029.7
Baseline: Negative clonal evolution80.075.064.9
Baseline: Missing0.00.05.4
W26D1: Positive clonal evolution10.050.08.1
W26D1: Negative clonal evolution80.025.064.9
W26D1: Missing10.025.027.0
W52D1: Positive clonal evolution025.02.7
W52D1: Negative clonal evolution30.025.029.7
W52D1: Missing70.050.067.6
W78D1: Positive clonal evolution025.00
W78D1: Negative clonal evolution40.025.021.6
W78D1: Missing60.050.078.4
W130D1: Positive clonal evolution000
W130D1: Negative clonal evolution30.008.1
W130D1: Missing70.0100.091.9
W182D1: Positive clonal evolution10.002.7
W182D1: Negative clonal evolution20.008.1
W182D1: Missing70.0100.089.2
W234D1: Positive clonal evolution002.7
W234D1: Negative clonal evolution30.002.7
W234D1: Missing70.0100.094.6
SecondaryExposure (AUCtau) - Response Relationship of Eltrombopag and Best Overall Response Rate by Age Groups

Pharmacokinetic parameter (AUCtau) of eltrombopag at the highest dose in relationship to best overall response rate in regard to complete response (CR), partial response (PR) and no response (NR). AUC tau: Area under the curve calculated to the end of the dosing interval (tau) (mass\*time/volume)

Time frame:
at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78
Reported as:
Geometric mean · hr*ng/mL
Exposure (AUCtau) - Response Relationship of Eltrombopag and Best Overall Response Rate by Age Groups
hr*ng/mLCohort A: Regimen 1 (1 to <6 Years)Cohort A: Regimen 1 (6 to <18 Years)Cohort A: Regimen 2 (6 to <18 Years)Cohort B (1 to <6 Years)Cohort B (6 to <18 Years)
No response (NR)816000390000—1260000 ± 27.0—
Complete response (CR)—769000 ± 87.3—2260000503000 ± 57.4
Partial response (PR)——1220000671000963000 ± 80.6
SecondaryExposure (Cmax, Ctrough) - Response Relationship of Eltrombopag and Best Overall Response Rate by Age Groups

Pharmacokinetic parameters (Cmax and Ctrough) of eltrombopag at the highest dose in relationship to overall response rate in regard to complete response (CR), partial response (PR) and no response (NR). Cmax is the observed maximum plasma concentration following administration (mass/volume). Ctrough is the pre-dose plasma concentration (mass/volume).

Time frame:
at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78
Reported as:
Geometric mean · ng/mL
Exposure (Cmax, Ctrough) - Response Relationship of Eltrombopag and Best Overall Response Rate by Age Groups
ng/mLCohort A: Regimen 1 (1 to <6 Years)Cohort A: Regimen 1 (6 to <18 Years)Cohort A: Regimen 2 (6 to <18 Years)Cohort B (1 to <6 Years)Cohort B (6 to <18 Years)
Cmax: No Response48400 ± 033900 ± 115—84900 ± 32.639200 ± 33.1
Cmax: Complete Response—35700 ± 88.3—11200031200 ± 63.7
Cmax: Partial Response——24800 ± 21260500 ± 26.654000 ± 54.4
Ctrough: No Response1640019900 ± 106—37800 ± 32.618500 ± 43.6
Ctrough: Complete Response—27000 ± 104—8470020100 ± 72.8
Ctrough: Partial Response——17100 ± 15123800 ± 19435300 ± 65.9
SecondaryExposure (AUCtau) - Response Relationship of Eltrombopag and Best Platelet Response Rate by Age Groups

Pharmacokinetic parameter (AUCtau) of eltrombopag at the highest dose in relationship to platelet response rate. AUC tau: Area under the curve calculated to the end of the dosing interval ( tau) (mass\*time/volume)

Time frame:
at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78
Reported as:
Geometric mean · hr*ng/mL
Exposure (AUCtau) - Response Relationship of Eltrombopag and Best Platelet Response Rate by Age Groups
hr*ng/mLCohort A: Regimen 1 (1 to <6 Years)Cohort A: Regimen 1 (6 to <18 Years)Cohort A: Regimen 2 (6 to <18 Years)Cohort B (1 to <6 Years)Cohort B (6 to <18 Years)
No Response816000———1280000
Complete Response—769000 ± 87.312200001670000 ± 45.2563000 ± 67.3
Partial Response—390000—1090000 ± 43.5—
SecondaryExposure (Cmax, Ctrough) - Response Relationship of Eltrombopag and Best Platelet Response Rate by Age Groups

Pharmacokinetic parameters (Cmax and Ctrough) of eltrombopag at the highest dose in relationship to platelet response rate. Cmax is the observed maximum plasma concentration following administration (mass/volume). Ctrough is the pre-dose plasma concentration (mass/volume).

Time frame:
at least 11 weeks after dose initiation or later when patients are taking the highest dose, up to Week 78
Reported as:
Geometric mean · ng/mL
Exposure (Cmax, Ctrough) - Response Relationship of Eltrombopag and Best Platelet Response Rate by Age Groups
ng/mLCohort A: Regimen 1 (1 to <6 Years)Cohort A: Regimen 1 (6 to <18 Years)Cohort A: Regimen 2 (6 to <18 Years)Cohort B (1 to <6 Years)Cohort B (6 to <18 Years)
Cmax: No Response4840064900——66600
Cmax: Complete Response—35700 ± 88.324800 ± 21280900 ± 31.735200 ± 65.8
Cmax: Partial Response—17700—74000 ± 42.139200 ± 33.1
Ctrough: No Response164001 ± 36800——45000
Ctrough: Complete Response—27000 ± 10417100 ± 15150100 ± 48.622700 ± 75.3
Ctrough: Partial Response—10800—24600 ± 13218500 ± 43.6
SecondaryAlternate Overall Response Rate (aORR)

Alternate overall responses were derived using hematological parameters (i.e., hemoglobin, platelet, reticulocyte, and ANC). aORR is defined as the percentage of participants who achieved an alternate complete response (aCR) or an alternate partial response (aPR)

Time frame:
Week 12, Week 26, Week 52, Week 78
Reported as:
Number · Percentage of participants
Alternate Overall Response Rate (aORR)
Percentage of participantsCohort A: Regimen 1Cohort A: Regimen 2Cohort B
Week 1290.0 (55.5 to 99.7)100 (39.8 to 100.0)64.9 (47.5 to 79.8)
Week 2690.0 (55.5 to 99.7)100 (39.8 to 100.0)75.7 (58.8 to 88.2)
Week 5260.0 (26.2 to 87.8)100 (39.8 to 100.0)40.5 (24.8 to 57.9)
Week 7850.0 (18.7 to 81.3)75.0 (19.4 to 99.4)48.6 (31.9 to 65.6)
SecondaryPharmacokinetics (PK) of Eltrombopag at the Starting Dose (AUCtau)

PK parameter, AUCtau. AUC tau: Area under the curve calculated to the end of the dosing interval (tau) (mass\*time/volume)

Time frame:
Week 3 Day 1
Reported as:
Geometric mean · hr*ng/mL
Pharmacokinetics (PK) of Eltrombopag at the Starting Dose (AUCtau)
hr*ng/mLCohort A: Regimen 1Cohort A: Regimen 2Cohort B
Pharmacokinetics (PK) of Eltrombopag at the Starting Dose (AUCtau)367000 ± 35.6350000 ± 47.7441000 ± 55.2
SecondaryPK of Eltrombopag at the Starting Dose (Cmax)

PK parameter, Cmax Cmax is the observed maximum plasma concentration following administration (mass/volume)

Time frame:
Week 3 Day 1
Reported as:
Geometric mean · ng/mL
PK of Eltrombopag at the Starting Dose (Cmax)
ng/mLCohort A: Regimen 1Cohort A: Regimen 2Cohort B
PK of Eltrombopag at the Starting Dose (Cmax)19700 ± 46.521000 ± 24.524000 ± 51.0
SecondaryPK of Eltrombopag at the Starting Dose (Ctrough)

PK parameter, Ctrough Ctrough is the pre-dose plasma concentration (mass/volume).

Time frame:
Week 3 Day 1
Reported as:
Geometric mean · ng/mL
PK of Eltrombopag at the Starting Dose (Ctrough)
ng/mLCohort A: Regimen 1Cohort A: Regiment 2Cohort B
PK of Eltrombopag at the Starting Dose (Ctrough)8760 ± 72.910900 ± 66.613200 ± 52.2
Post-hocAll Collected Deaths

On-treatment deaths were collected from the first dose of study treatment up to 30 days after last dose of study medication, for a maximum duration of 234 weeks. Post-treatment survival follow-up deaths were collected 31 days after last dose of study medication until date of the last follow-up for the primary analysis, up to 234 weeks.

Time frame:
On-treatment deaths: from first dose of study treatment up to 30 days post treatment, approx. 234 weeks; Post-treatment survival follow-up deaths: from Day 31 to approx. 234 weeks
Reported as:
Number · Participants
All Collected Deaths
ParticipantsCohort A: Regiment 1Cohort A: Regimen 2Cohort BTotal (Cohorts A (Regimen 1 & 2) and B
Total deaths0101
On-treatment deaths0000
Post-treatment deaths0101

Adverse events

Collected over Adverse Events (AEs) were collected from first dosing (Day 1) until date of the last follow-up, up to 30 weeks. Deaths were collected from randomization to end of study, up to 234 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A - Regimen 1 (On-treatment)0/10 (0%)4/10 (40%)10/10 (100%)
Cohort A - Regimen 2 (On-treatment)0/4 (0%)2/4 (50%)4/4 (100%)
Total Cohort A (Regiments 1 & 2) (On-treatment)0/14 (0%)6/14 (42.9%)14/14 (100%)
Cohort B (On-treatment)0/37 (0%)23/37 (62.2%)37/37 (100%)
Total Participants (On-treatment)0/51 (0%)29/51 (56.9%)51/51 (100%)
Cohort A - Regimen 1 (Post--treatment)0/10 (0%)——
Cohort A - Regimen 2 (Post-treatment)1/4 (25%)——
Total Cohort A (Regimens 1 & 2) (Post-treatment)1/14 (7.1%)——
Cohort B (Post-treatment)0/37 (0%)——
All Participants (Cohorts A & B) (Post-treatment)1/51 (2%)——
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventCohort A - Regimen 1 (On-treatment)Cohort A - Regimen 2 (On-treatment)Total Cohort A (Regiments 1 & 2) (On-treatment)Cohort B (On-treatment)Total Participants (On-treatment)Cohort A - Regimen 1 (Post--treatment)Cohort A - Regimen 2 (Post-treatment)Total Cohort A (Regimens 1 & 2) (Post-treatment)Cohort B (Post-treatment)All Participants (Cohorts A & B) (Post-treatment)
Febrile neutropeniaBlood and lymphatic system disorders1/101/42/145/377/51—————
StomatitisGastrointestinal disorders0/101/41/140/371/51—————
PyrexiaGeneral disorders2/101/43/148/3711/51—————
Drug-induced liver injuryHepatobiliary disorders0/101/41/140/371/51—————
Clostridium difficile infectionInfections and infestations0/101/41/140/371/51—————
GastroenteritisInfections and infestations0/101/41/141/372/51—————
Staphylococcal infectionInfections and infestations0/101/41/141/372/51—————
Acute kidney injuryRenal and urinary disorders0/101/41/142/373/51—————
Renal failureRenal and urinary disorders0/101/41/140/371/51—————
Septic shockInfections and infestations1/100/41/140/371/51—————
Most frequent other events
Showing 10 of 155
Most frequent other events
EventCohort A - Regimen 1 (On-treatment)Cohort A - Regimen 2 (On-treatment)Total Cohort A (Regiments 1 & 2) (On-treatment)Cohort B (On-treatment)Total Participants (On-treatment)Cohort A - Regimen 1 (Post--treatment)Cohort A - Regimen 2 (Post-treatment)Total Cohort A (Regimens 1 & 2) (Post-treatment)Cohort B (Post-treatment)All Participants (Cohorts A & B) (Post-treatment)
Gingival hypertrophyGastrointestinal disorders0/103/43/144/377/51—————
Blood urea increasedInvestigations4/103/47/145/3712/51—————
Alanine aminotransferase increasedInvestigations7/101/48/1416/3724/51—————
Aspartate aminotransferase increasedInvestigations6/101/47/1413/3720/51—————
Blood bilirubin increasedInvestigations6/100/46/1418/3724/51—————
Abdominal painGastrointestinal disorders1/102/43/1413/3716/51—————
VomitingGastrointestinal disorders1/102/43/1418/3721/51—————
Blood creatinine increasedInvestigations5/102/47/1413/3720/51—————
Pain in extremityMusculoskeletal and connective tissue disorders2/102/44/145/379/51—————
ErythemaSkin and subcutaneous tissue disorders0/102/42/141/373/51—————

Baseline characteristics

Full analysis Set (FAS): FAS comprised all patients to whom study treatment had been assigned.

Age, Continuous
Age, Continuous(Years)Cohort A: Regimen 1Cohort A: Regimen 2Cohort BTotal
Median12.0 (4.0 to 17.0)10.0 (7.0 to 12.0)10.0 (2.0 to 17.0)10.0 (2.0 to 17.0)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: Regimen 1Cohort A: Regimen 2Cohort BTotal
Female511723
Male532028
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A: Regimen 1Cohort A: Regimen 2Cohort BTotal
Caucasian422430
Black2147
Asian31913
Unknown1001
08

Study locations

20 sites
  • Phoenix Childrens Hospital
    Phoenix, Arizona 85016, United States
  • Arkansas Childrens Hospital
    Little Rock, Arkansas 72202, United States
  • Childrens Hospital Colorado
    Aurora, Colorado 80045, United States
  • Aflac Cancerand Blood Disorders Ctr
    Atlanta, Georgia 30342, United States
  • Ann and Robert H Lurie Childs Hosp
    Chicago, Illinois 60611, United States
  • Indiana University
    Indianapolis, Indiana 46202-5225, United States
  • Childrens Hosp Boston Dept of Heme
    Boston, Massachusetts 02115, United States
  • University of MI Health System
    Ann Arbor, Michigan 48109, United States
  • Hackensack University Medical Center SC-2
    Hackensack, New Jersey 07601, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Texas Childrens Cancer and Hematology Center
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Hong Kong, 999077, Hong Kong
  • Novartis Investigative Site
    Lisbon, 1649-035, Portugal
  • Novartis Investigative Site
    Moscow, 117198, Russia
  • Novartis Investigative Site
    Saint Petersburg, 197022, Russia
  • Novartis Investigative Site
    Khon Kaen, THA 40002, Thailand
  • Novartis Investigative Site
    Bangkok, 10400, Thailand
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    London, WC1N 3JH, United Kingdom
09

References and documents

Publications

  • Shimamura A, Maschan A, Bennett C, Samarasinghe S, Farrar JE, Li CK, Sirachainan N, Pongtanakul B, Komvilaisak P, Zubarovskaya L, Rothman JA, Walkovich K, Nakano TA, Bertuch AA, Ferrao A, Bhat R, Hanna R, Overholt K, Boklan J, Wong TF, Wang Q, Urban P, Strahm B, Wang W, Vlachos A, Williams DA. Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial. Blood Adv. 2025 Aug 12;9(15):3728-3738. doi: 10.1182/bloodadvances.2024015102. PubMed 40315366 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided are anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Apr 2022, 54 months.

Results were first posted in Aug 2026, 4 years 3 months after primary completion. A results delay was requested in Mar 2023.

Of 60 phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 104. This study's 54 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2017
First posted
Jan 19, 2017
StartActual
Sep 30, 2017
Primary completionActual
Apr 22, 2022
CompletionActual
Jan 27, 2025
Results delay requested
Mar 24, 2023
Results first posted
Aug 10, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03025698
Responsible party
Sponsor
First posted
Jan 19, 2017
Start date
Sep 30, 2017
Primary completion
Apr 22, 2022
Completion
Jan 27, 2025
Results posted
Aug 10, 2026
Last update
Aug 10, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion